Evidence map›Paper›PMID 33953709›Full record

ArticleFrontiers in immunology2021

A Comparison Between Recombinant

Hector Teran-Navarro, David Salcines-Cuevas, Ricardo Calderon-Gonzalez, Raquel Tobes, Jorge Calvo-Montes, Inmaculada Concepción Pérez-Del Molino Bernal, Sonsoles Yañez-Diaz, Manuel Fresno, Carmen Alvarez-Dominguez

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Hector Teran-NavarroInstituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
David Salcines-CuevasInstituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
Ricardo Calderon-GonzalezInstituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
Raquel TobesAlamo Blanco, Granada, Spain.
Jorge Calvo-MontesMicrobiology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Inmaculada Concepción Pérez-Del Molino BernalMicrobiology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Sonsoles Yañez-DiazDermatology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Manuel FresnoDIOMUNE S.L., Parque Científico de Madrid, Madrid, Spain.
Carmen Alvarez-DominguezFacultad de Educación y Facultad de Ciencias de la Salud, Universidad Internacional de La Rioja, Logroño, Spain.
Instituto de Investigación Marqués de Valdecilla · ESMarqués de Valdecilla University Hospital · ESUnidades Centrales Científico-Técnicas · ESUniversidad de Cantabria · ESUniversidad Internacional De La Rioja · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cross-reactive vaccines recognize common molecular patterns in pathogens and are able to confer broad spectrum protection against different infections. Antigens common to pathogenic bacteria that induce broad immune responses, such as the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) of the genera

Indexed as

Adjuvants, ImmunologicAnimalsAntibodies, BacterialAntigens, BacterialBacterial InfectionsBacterial VaccinesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCross ProtectionCross ReactionsDendritic CellsGlyceraldehyde-3-Phosphate DehydrogenasesInterferon-gammaLipidsListeriaMiceAdjuvants, ImmunologicAntibodies, BacterialAntigens, BacterialBacterial VaccinesGlyceraldehyde-3-Phosphate DehydrogenasesInterferon-gammaLipidsRecombinant ProteinsRNA, Messengercross-reactive vaccinesglyceraldehyde-3-phosphate-dehydrogenaseinnate immunitylisteriosispneumoniatuberculosis

Identifiers

PMID33953709
PMCPMC8092121
OpenAlexW3155161854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.